~0 spots leftby Mar 2026

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Recruiting in Palo Alto (17 mi)
+23 other locations
Overseen ByPaula R Pohlmann, MD, MSc, PhD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: QuantumLeap Healthcare Collaborative
No Placebo Group

Trial Summary

What is the purpose of this trial?This trial tests a new treatment for patients with specific types of advanced cancer. It aims to deliver medicine directly to cancer cells, making the treatment more effective and potentially reducing side effects.

Eligibility Criteria

Participant Groups

1Treatment groups
Experimental Treatment
Group I: Vic-trastuzumab duocarmazine (SYD985) + paclitaxelExperimental Treatment1 Intervention
Single-arm, phase I trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel. The study contains 2 cohorts. Cohort A is the de-escalation cohort. Patients with certain HER-positive advanced solid tumors or HER2-low breast cancer will be enrolled in this cohort. Cohort B is the expansion cohort, in which only patients with HER2-positive or HER2-low breast cancer can be enrolled. Treatment will be administered on an outpatient basis.

Find A Clinic Near You

Research locations nearbySelect from list below to view details:
University of Colorado Cancer CenterAurora, CO
University of ChicagoChicago, IL
University of Alabama at BirminghamBirmingham, AL
University of Southern CaliforniaLos Angeles, CA
More Trial Locations
Loading ...

Who is running the clinical trial?

QuantumLeap Healthcare CollaborativeLead Sponsor
Byondis B.V.Industry Sponsor

References